Secondary Logo

Institutional members access full text with Ovid®

Risk of Gastric and Colorectal Cancer After Tamoxifen Use for Breast Cancer

A Systematic Review and Meta-Analysis

Chen, Shicai, PhD; Liu, Haiying, PhD; Li, Jianchang, MD; Yang, Guohua, MD

Journal of Clinical Gastroenterology: September 2015 - Volume 49 - Issue 8 - p 666–674
doi: 10.1097/MCG.0000000000000262
ALIMENTARY TRACT: Original Articles
Buy
SDC

Objective: It is still controversial whether tamoxifen use for breast cancer will simultaneously cause gastric and colorectal cancer. In this study, we aimed to evaluate the association between tamoxifen use and the risk of gastric and colorectal cancer by performing a systematic review and meta-analysis.

Materials and Methods: A comprehensive literature search for relevant studies published from 1969 to October 2013 was performed in PubMed, MEDLINE, and ISI Web of Science. Only articles in which gastric and colorectal cancer was reported after tamoxifen therapy for breast cancer were included. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using both the random-effects and fixed-effects models.

Results: We found a total of 9 studies that met the inclusion criteria for the analysis of tamoxifen use and incidence of gastric and colorectal cancer. Among these studies, 7 were involved with both gastric and colorectal cancer, 1 with gastric cancer and 1 with colorectal cancer. The random-effects model results showed that tamoxifen use for breast cancer was not a risk factor for either gastric cancer (RR=0.92; 95% CI, 0.41-2.07, P=0.84) or colorectal cancer (RR=1.05; 95% CI, 0.90-1.21, P=0.54). Sensitivity analysis indicated that the duration or dose of tamoxifen use had no effect on these 2 gastrointestinal tumors (P>0.05). Stratified analysis showed that tamoxifen use was not associated with the increased risk of gastric and colorectal cancer regardless of whether the latency interval after breast cancer diagnosis was <5 or ≥5 years.

Conclusion: Our meta-analysis results indicate that there was no substantial increase in gastric and colorectal cancer among the tamoxifen-treated female patients.

Department of Gastrointestinal Tumor Surgery, Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong Province, China

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website, www.jcge.com.

S.C.: manuscript writing, provision of study material and patients; H.L.: conception and design, final approval of manuscript; J.L.: collection and assembly of data; G.Y.: data analysis and interpretation.

Supported by Educational Commission of Guangdong Province, China (2013LYM0069) and the Doctoral Research Foundation of Guangzhou Medical University (2011C 57).

The authors declare that they have nothing to disclose.

Reprints: Haiying Liu, PhD, Department of Gastrointestinal Tumor Surgery, Cancer Center of Guangzhou Medical University, #78 Hengzhigang Road, Guangzhou 510095, Guangdong Province, China (e-mail: gzlhy20110701@163.com).

Received April 6, 2014

Accepted September 11, 2014

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.